FDA Warns RonanRx Over 'American Made' Compounded Semaglutide and Tirzepatide, Saying No U.S. Plant Is Listed as the Drug Substance Maker

The FDA has posted a warning letter to RonanRx, an online seller of compounded semaglutide and tirzepatide, over how it markets them. The letter is dated 30 October 2026 and was posted on fda.gov on 3 November. It names three kinds of claim the agency calls false or misleading, and in answering one of them it makes a statement that reaches beyond this seller: none of the FDA's drug listings for semaglutide or tirzepatide active ingredient meant for compounding names a U.S. plant as the maker. Here is what the letter says and what it leaves open, as of 8 November 2026.

The letter in brief

Source: FDA warning letter to RonanRx, MARCS-CMS 737905, 30 October 2026, read on fda.gov on 8 November 2026.

The three claims the FDA objects to

1. A name on the label that is not the compounder's

The FDA says the compounded tirzepatide products shown on RonanRx's website and posted on X "identify 'RonanRx' on the pictured label, suggesting RonanRx is the compounder of those drugs when in fact it is not." The letter does not name the pharmacy that does compound them. One of the steps it asks RonanRx to take is "identifying the entities that produce the compounded drug products offered on your website."

2. Claims that read as FDA approval

The letter quotes two category labels from the website: "Well-Studied Compounded Medications" and "FDA-Approved Compounded Medications", the second described as "Compounded medications whose active ingredient has at least one FDA-approved branded form for the indication described." On X it quotes the account's bio, "Explore GLP-1s like Ozempic", and a pinned video offering "seventy-eight dollars a month, for drugs like Ozempic". The FDA's answer is plain: "Compounded drug products are not FDA-approved." It adds that disclaimers saying a preparation "may not itself be FDA-approved" do not "cure the misleading overall impression created by these claims."

3. "American made" and "farm-to-table drugs"

The same video, the FDA says, called the products "American made" and "farm-to-table drugs" and ended with an American flag and confetti. The agency's reply is the sentence that matters beyond this one seller:

"FDA's records contain no drug listings for semaglutide or tirzepatide active pharmaceutical ingredients, intended for use in compounding, that identify a United States establishment registered with the FDA as the drug substance manufacturer."

From that, the FDA concludes that "the active pharmaceutical ingredient in the product was not made in the U.S.", so the "American made" claim gives a misleading impression of where the product comes from. The letter rests this on FDA listing records. It does not say which country the ingredient comes from, and it does not test any product.

How it fits the pattern

The first two points repeat what the FDA has raised with telehealth sellers all year. When it announced 30 warning letters on 3 March 2026, the agency said the main violations were "claims implying sameness with FDA-approved products and obscuring product sourcing by advertising drug products branded with the telehealth firm's name or trademark without qualification, implying they are the compounder." A second batch, to 25 telehealth companies, followed on 16 June. Our enforcement tracker lists both batches, the 18 September letter to Empower Pharmacy, and now this one.

The policy direction for these two drugs has not changed either. The HHS enforcement discretion policy published on 30 October covers six peptides, BPC-157, epitalon, KPV, MOTS-c, semax and TB-500, and not semaglutide or tirzepatide (what that policy says). For outsourcing facilities, the FDA proposed in April 2026 to keep semaglutide, tirzepatide and liraglutide off the 503B bulks list.

What the letter does not say

• No harm, no test results. The letter is about claims. It reports no laboratory testing of RonanRx's products and no adverse events. We are not saying the products are unsafe; the FDA's letter does not say so either.
• Not a recall, not a finding of a court. A warning letter is the FDA's notice of what it considers violations and a chance to fix them. RonanRx may dispute it. No response is posted with the letter on fda.gov as of 8 November.
• Not about where every compounded GLP-1 is finished. The listing point is about the active ingredient. Compounding itself is done by pharmacies, and the letter does not say where RonanRx's products were compounded.
• Nothing on research-use-only products. The letter concerns compounded prescription drugs. The FDA's earlier letters to research-peptide sellers are a separate line of action, listed in the tracker.

What to watch

Whether RonanRx's website and X account change, whether the FDA posts a response or close-out letter, and whether the "no U.S. listing" point appears in further letters. We will add any of these to this page and the tracker with the date we read it. This page is news on a regulatory record, not medical advice; prescription drugs are a matter for a licensed prescriber.

Questions readers ask

Sources

1. FDA warning letter to RonanRx, Inc. dba RonanRx, MARCS-CMS 737905, letter of 30 October 2026; posted 3 November 2026; read 8 November 2026
2. FDA warning letters database (search: compounded, semaglutide, tirzepatide), read 8 November 2026
3. FDA: FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s, 3 March 2026
4. RAPS Regulatory Focus: FDA cites telehealth firms for illegally marketing GLP-1 drugs (25 letters), 16 June 2026
5. FDA: FDA proposes to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, 30 April 2026
6. Federal Register: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (91 FR 68526), 30 October 2026